Show simple item record

dc.contributor.author Szentmártoni, Gyöngyvér
dc.contributor.author Tőkés, Anna-Mária
dc.contributor.author Tőkés, Tímea
dc.contributor.author Somlai, K
dc.contributor.author Szász, Attila Marcell
dc.contributor.author Torgyik, László
dc.contributor.author Kulka, Janina
dc.contributor.author Dank, Magdolna
dc.date.accessioned 2020-03-25T10:35:15Z
dc.date.available 2020-03-25T10:35:15Z
dc.date.issued 2016
dc.identifier 84971529583
dc.identifier.citation journalVolume=57;journalIssueNumber=2;journalTitle=CROATIAN MEDICAL JOURNAL;pagerange=131-139;journalAbbreviatedTitle=CROAT MED J;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/7461
dc.identifier.uri doi:10.3325/cmj.2016.57.131
dc.description.abstract AIM: To identify breast cancer subtypes likely to respond to primary systemic therapy (PST or neoadjuvant therapy) and to assess the accuracy of physical examination (PE) and breast ultrasonography (US) in evaluating and predicting residual size of breast carcinoma following PST. METHODS: 116 patients who received at least two cycles of PST between 1998 and 2009 were selected from a prospectively collected clinical database. Radiological assessment was done by mammography and US. Prior to PST, tumors were subclassified according to core biopsy (NCB) and/or fine-needle aspiration-based immunohistochemical profiles of NCB. Pathological response rates were assessed following the surgeries by using Chevallier classification. Tumor measurements by PE and US were obtained before and after PST. Different clinical measurements were compared with histological findings. Disease-free survival (DFS) was assessed. RESULTS: Pathological complete remission (pCR=Chevallier I/II) was observed in 25 patients (21.5%), 44% of whom had triple negative histology, 28% Her2 positive and 76% had high-grade tumor. Of 116 patients, 24 received taxane-based PST, 48 combined taxane + anthracycline treatment, 8 trastuzumab combinations, 21 anthracycline-based treatments, and 15 other treatments. In the taxane treated group, the pCR rate was 30%, in the taxane + anthracycline group 25%, in the anthracycline group 9.5%, and in trastuzumab group 37.5%. After PST, PE and US were both significantly associated with pathology (P<0.001 and P=0.004, respectively). Concerning OS, significant difference was observed between the Chevallier III and IV group (P=0.031) in favor of Chevallier III group. In the pCR group, fewer events were observed during the follow-up period. CONCLUSIONS: Our results show that even limited, routinely used immunohistochemical profiling of tumors can predict the likelihood of pCR to PST: patients with triple negative and Her2-positive cancers are more likely to achieve pCR to PST. Also, PE is better correlated with pathological findings than US.
dc.format.extent 131-139
dc.relation.ispartof urn:issn:0353-9504
dc.title Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival
dc.type Journal Article
dc.date.updated 2019-08-13T15:04:04Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 3060175
dc.identifier.wos 000377053400006
dc.identifier.pubmed 27106355
dc.contributor.department SE/AOK/K/Radiológiai és Onkoterápiás Klinika
dc.contributor.department SE/AOK/I/II. Sz. Patológiai Intézet
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account